These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 24661663)

  • 1. No clinically significant changes in pulmonary function following stereotactic body radiation therapy for early- stage peripheral non-small cell lung cancer: an analysis of RTOG 0236.
    Stanic S; Paulus R; Timmerman RD; Michalski JM; Barriger RB; Bezjak A; Videtic GM; Bradley J
    Int J Radiat Oncol Biol Phys; 2014 Apr; 88(5):1092-9. PubMed ID: 24661663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of a dose-effect relationship for pulmonary function changes after stereotactic body radiation therapy for early-stage non-small cell lung cancer.
    Guckenberger M; Klement RJ; Kestin LL; Hope AJ; Belderbos J; Werner-Wasik M; Yan D; Sonke JJ; Bissonnette JP; Xiao Y; Grills IS
    Int J Radiat Oncol Biol Phys; 2013 Mar; 85(4):1074-81. PubMed ID: 23154077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pulmonary function and quality of life after VMAT-based stereotactic ablative radiotherapy for early stage inoperable NSCLC: a prospective study.
    Ferrero C; Badellino S; Filippi AR; Focaraccio L; Giaj Levra M; Levis M; Moretto F; Torchio R; Ricardi U; Novello S
    Lung Cancer; 2015 Sep; 89(3):350-6. PubMed ID: 26164208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive analysis of pulmonary function Test (PFT) changes after stereotactic body radiotherapy (SBRT) for stage I lung cancer in medically inoperable patients.
    Stephans KL; Djemil T; Reddy CA; Gajdos SM; Kolar M; Machuzak M; Mazzone P; Videtic GM
    J Thorac Oncol; 2009 Jul; 4(7):838-44. PubMed ID: 19487961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Marginal pulmonary function should not preclude lobectomy in selected patients with non-small cell lung cancer.
    Taylor MD; LaPar DJ; Isbell JM; Kozower BD; Lau CL; Jones DR
    J Thorac Cardiovasc Surg; 2014 Feb; 147(2):738-44; Discussion 744-6. PubMed ID: 24252944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is there a lower limit of pretreatment pulmonary function for safe and effective stereotactic body radiotherapy for early-stage non-small cell lung cancer?
    Guckenberger M; Kestin LL; Hope AJ; Belderbos J; Werner-Wasik M; Yan D; Sonke JJ; Bissonnette JP; Wilbert J; Xiao Y; Grills IS
    J Thorac Oncol; 2012 Mar; 7(3):542-51. PubMed ID: 22258475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II Trial of SBRT for Stage I NSCLC: Survival, Local Control, and Lung Function at 36 Months.
    Navarro-Martin A; Aso S; Cacicedo J; Arnaiz M; Navarro V; Rosales S; de Blas R; Ramos R; Guedea F
    J Thorac Oncol; 2016 Jul; 11(7):1101-11. PubMed ID: 27103512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A dose-volume analysis of radiation pneumonitis in non-small cell lung cancer patients treated with stereotactic body radiation therapy.
    Barriger RB; Forquer JA; Brabham JG; Andolino DL; Shapiro RH; Henderson MA; Johnstone PA; Fakiris AJ
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):457-62. PubMed ID: 21035956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lung stereotactic body radiation therapy for elderly patients aged ≥ 80 years with pathologically proven early-stage non-small cell lung cancer: a retrospective cohort study.
    Watanabe K; Katsui K; Sugiyama S; Yoshio K; Kuroda M; Hiraki T; Kiura K; Maeda Y; Toyooka S; Kanazawa S
    Radiat Oncol; 2021 Feb; 16(1):39. PubMed ID: 33622369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in Pulmonary Function Following Image-Guided Stereotactic Lung Radiotherapy: Neither Lower Baseline Nor Post-SBRT Pulmonary Function Are Associated with Worse Overall Survival.
    Stone B; Mangona VS; Johnson MD; Ye H; Grills IS
    J Thorac Oncol; 2015 Dec; 10(12):1762-9. PubMed ID: 26334751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baseline pulmonary function as a predictor for survival and decline in pulmonary function over time in patients undergoing stereotactic body radiotherapy for the treatment of stage I non-small-cell lung cancer.
    Henderson M; McGarry R; Yiannoutsos C; Fakiris A; Hoopes D; Williams M; Timmerman R
    Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):404-9. PubMed ID: 18394819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stereotactic Body Radiation Therapy for Operable Early-Stage Lung Cancer: Findings From the NRG Oncology RTOG 0618 Trial.
    Timmerman RD; Paulus R; Pass HI; Gore EM; Edelman MJ; Galvin J; Straube WL; Nedzi LA; McGarry RC; Robinson CG; Schiff PB; Chang G; Loo BW; Bradley JD; Choy H
    JAMA Oncol; 2018 Sep; 4(9):1263-1266. PubMed ID: 29852037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of tumor size on outcomes after stereotactic body radiation therapy for medically inoperable early-stage non-small cell lung cancer.
    Allibhai Z; Taremi M; Bezjak A; Brade A; Hope AJ; Sun A; Cho BC
    Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):1064-70. PubMed ID: 24210082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stereotactic body radiation therapy for re-irradiation of persistent or recurrent non-small cell lung cancer.
    Trovo M; Minatel E; Durofil E; Polesel J; Avanzo M; Baresic T; Bearz A; Del Conte A; Franchin G; Gobitti C; Rumeileh IA; Trovo MG
    Int J Radiat Oncol Biol Phys; 2014 Apr; 88(5):1114-9. PubMed ID: 24661664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stereotactic body radiation therapy can be used safely to boost residual disease in locally advanced non-small cell lung cancer: a prospective study.
    Feddock J; Arnold SM; Shelton BJ; Sinha P; Conrad G; Chen L; Rinehart J; McGarry RC
    Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1325-31. PubMed ID: 23265574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of Monte Carlo algorithm for compliance with RTOG 0915 dosimetric criteria in peripheral lung cancer patients treated with stereotactic body radiotherapy.
    Pokhrel D; Sood S; Badkul R; Jiang H; McClinton C; Lominska C; Kumar P; Wang F
    J Appl Clin Med Phys; 2016 May; 17(3):277-293. PubMed ID: 27167284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of Pneumonitis After Stereotactic Body Radiation Therapy in Patients With Previous Anatomic Lung Resection.
    Hayes JT; David EA; Qi L; Chen AM; Daly ME
    Clin Lung Cancer; 2015 Sep; 16(5):379-84. PubMed ID: 25737143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can serum markers be used to predict acute and late toxicity in patients with lung cancer? Analysis of RTOG 91-03.
    Hartsell WF; Scott CB; Dundas GS; Mohiuddin M; Meredith RF; Rubin P; Weigensberg IJ
    Am J Clin Oncol; 2007 Aug; 30(4):368-76. PubMed ID: 17762437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors for symptomatic radiation pneumonitis after stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer.
    Liu Y; Wang W; Shiue K; Yao H; Cerra-Franco A; Shapiro RH; Huang KC; Vile D; Langer M; Watson G; Bartlett G; Ai H; Sheski F; Jin JY; Zellars R; Fu P; Lautenschlaeger T; Kong FS
    Radiother Oncol; 2021 Mar; 156():231-238. PubMed ID: 33096168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereotactic body radiation therapy for early-stage non-small-cell lung cancer: the pattern of failure is distant.
    Bradley JD; El Naqa I; Drzymala RE; Trovo M; Jones G; Denning MD
    Int J Radiat Oncol Biol Phys; 2010 Jul; 77(4):1146-50. PubMed ID: 19800181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.